Browse > Article

Improving Productivity of Pravastatin, HMG-CoA Reductase Inhibitor  

Jeon, Dong-Soo (Department of Food Engineering, Dankook University)
Bai, Dong-Hoon (Department of Food Engineering, Dankook University)
Publication Information
Food Engineering Progress / v.13, no.4, 2009 , pp. 243-250 More about this Journal
Abstract
Pravastatin sodium, competitive inhibitors of HMG-CoA(3-hydroxy-3-methylglutaryl coenzyme A) reductase, is produced from the culture broth of Streptomyces carbophilus KCCM 10370, The production of Pravastatin sodium was increased about 45 fold compared to wild type by UV mutation. Production of Pravastatin was also improved by continuous feeding of Compactin sodium to 24% and bioconversion ratio was also increased to 4.3% by intermittent addition. In main culture, concentration of Compactin sodium was kept less than 0.1%(w/v) under continuous feeding of Compactin sodium then product was 0.49% and bioconversion was 70%. After finishing the fermentation, Pravastatin was purified by various chromatographies such as Diaion HP20 resin column, Partition, and ODS(Octa-Decylsilyl Silicagel) resin column with a final yield of 70~72% and over 99.7% purity. The IR, UV, and NMR study of the purified Pravastatin sodium showed the same pattern as that of EP(European Pharmacopoeia).
Keywords
Streptomyces carbophilus; Pravastatin; Compactin; HMG-CoA reductase inhibitor;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Endo A, Kuroda M, Tsujita Y. 1976. ML-236A, ML-236B andML-236C, new inhibitors of cholestero genesis produced byPenicillium citrinum. J. Antibiot. 29: 1346-1348   DOI   PUBMED
2 Masahiko H, Ogawa K, Yoshikawa H. 1993. Morphology study inproduction of ML-236B, a precursor of pravastatin sodium, byPenicillium citrinum. J. Ferment. Bioeng. 76: 470-475   DOI   ScienceOn
3 Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, BaumerAT, Linz W, Bohm M, Nickenig G. 2002. Cellular antioxidanteffects of atrovastatin in vitro and in vivo. Arteriolscler ThrombVasc Biol. 22: 300-305   DOI   ScienceOn
4 Dietschy JM, Wilson JD. 1970. Regulation of cholesterol metabolism.N. Engl. J. Med., 282: 1179-1183   DOI   PUBMED   ScienceOn
5 Tobert JA. 1987. New developments in lipid-lowering therapy :the role of inhibiters of hydroxymethyl-glutaryl-coenzyme Areductase, Circulation, 76(3), 534-538   DOI   PUBMED   ScienceOn
6 Endo A, and Kuroda M. 1976. Citrinin, an inhibitor of cholesterolsynthesis. J. Antibiotics. 29: 841-843   DOI   PUBMED
7 Witkin EM. 1976. Ultraviolet mutagenesis and inducible DNArepair in Escherichia coli. Bacteriol. Rev. 40: 869-907   PUBMED   ScienceOn
8 Nobufusa S, Hosobuchi N, and Yoshikawa H. 1996. Biochemicaland molecular-approaches for production of Pravastatin, a potentcholesterol-lowering drug. Biotech. Ann. Rev. 2; 373-389   DOI   PUBMED   ScienceOn
9 Miller GL. 1959. Use of dinitrosalicylic acid regent for determinationof reducing Suar. Anal. Chem. 31: 426-428   DOI
10 Tsujita Y, Kuroda M, Shimada T, Tanzawa K, Arai M, Kaneko I,Tanaka M, Masuda H, Tarumi C, Watanabe Y, Fujii S. 1986.CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase : tissue-selective inhibition of sterol synthesisand hypolipidemic effect on various animal species. Biochim.Biophys. Acta. 877: 50-60   DOI   PUBMED   ScienceOn
11 Serizawa N, Nakagawa K, Hamano K, Tsujita Y, Terahara A,Kuwano H. 1983. Microbial hydroxylation of ML-236B(compactin)and monacolin K. J. Antibiot. 36: 604-607   DOI   PUBMED
12 Cleeman JI. 2001. Executive Summary of The Third Report ofThe National Cholesterol Education Program(NCEP) ExpertPanel on Detection, Evaluation, And Treatment of High BloodCholesterol In Adults JAMA. 285(19): 2486-2497   DOI   ScienceOn
13 Freeman DJ, Norrie J, Sttar N, Neely DG, Cobbe SM, Ford I,Isles C, Lorimer AR, Macfarlane PW, McKillop JH, PackardCJ, Shepherd J, Gaw A. 2001. Pravastatin and the developmentof diabetes mellitus: Evidence for a protective treatment effectin the West of Scotland Coronary Prevention Study. Circulation103: 357-362   DOI   PUBMED   ScienceOn
14 Hideyuki H, Harumitsu K, Takeshi K, Akira T, Takashi N. 1986.Structure elucidation of bioactive metabolites of ML-236B(Mevastatin)isolated from dog urine. Chem. Pharm. Bull. 34: 1459-1467   DOI   PUBMED   ScienceOn
15 Kiyoshima K, Takada K, Yamamoto M, Kubo K, Okamoto R,Fukagaway, Ishikura T, Naganawa H, Sawa T, Takeuchi, UmexawaH. 1987. New tylosin anologs produced by mutants ofStreptomyces fradiae. J. Antibiot. 40: 1123-1130   DOI   PUBMED
16 Stryer L.1995. Biochemistry (4th ed). W.H. Freeman and CompanyVirginia, USA, pp. 685-712
17 Hosobuchi M, Testsuya S, Masatoshi A, Jo O, Seigo I, Hiroji Y.1992. Production of ML-236B, and inhibitor of 3-hydroxy-3-methylglutaryl Co A reductase, by Penicillium citrinum :Improvements of strain and culture conditions. Biosci. Biotech.Biochem. 57: 1414-1419   DOI
18 Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S,Takeshima A. 2001. Antiinflammatory and antiarterioscleroticactions of HMG-CoA reductase inhibitor in a rat model ofchronic inhibition of nitric oxide synthesis. Circ. Res. 89: 415-421   DOI   ScienceOn
19 Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M,Monopoli A, Soldato PD, Ignarro LJ. 2004. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhancedantiproliferative and antiinflammatory properties. Proc. Natl.Acad. Sci. 101: 8497-8502   DOI   ScienceOn